Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Year range
1.
Femina ; 38(7): 373-378, jul. 2010.
Article in Portuguese | LILACS | ID: lil-566915

ABSTRACT

A síndrome pré-menstrual (SPM) caracteriza-se por um conjunto de sintomas físicos, emocionais e comportamentais, cíclicos e recorrentes que iniciam na semana anterior à menstruação e aliviam com o início do fluxo, sendo um distúrbio altamente prevalente entre as mulheres em idade fértil. Enquetes epidemiológicas mostram que 75 a 80% das mulheres apresentam sintomas durante o período pré-menstrual. A revisão de literatura, entretanto, mostrou que o assunto está longe de um consenso, com controvérsias sobre fatores de risco, proteção e tratamento. Uma vez confirmado o diagnóstico, modificações no estilo de vida, suplemento de cálcio, vitamina B12 e V. agnus castus são opções não-farmacológicas razoáveis. Os inibidores seletivos de recaptação da serotonina (ISRS) são atualmente considerados a classe farmacológica mais efetiva. Outra opção é o uso de anticoncepcionais orais (ACO) combinados com etinilestradiol (EE) e drospirenona que foram aprovados pela Food and Drug Administration (FDA) para o tratamento da SPM e do transtorno disfórico pré-menstrual (TDPM)


The premenstrual syndrome (PMS) is characterized by a set of physical symptoms, emotional and behavioral, cyclical and recurring that start in the week before menstruation and relieve the beginning of the stream, being a highly prevalent disorder among women of childbearing age. Epidemiological surveys show that 75 to 80% of women experience symptoms during the premenstrual period. The literature review, however, showed that the subject is far from a consensus, with controversies about risk factors, protection and treatment. Once the diagnosis is confirmed, changes in lifestyle, calcium supplement, vitamin B12 and V. agnus castus are pharmacologic reasonable options. The selective serotonin reuptake inhibitors (SSRIs) are currently considered the most effective pharmacological class. Another option is the use of oral contraceptive combined with drospirenone and ethinilestradiol (EE) which were approved by the Food and Drug Administration (FDA) for the treatment of PMS and premenstrual dysphoric disorder (PMDD)


Subject(s)
Humans , Female , Adult , Contraceptives, Oral/therapeutic use , Calcium, Dietary/administration & dosage , Ethinyl Estradiol/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Premenstrual Syndrome/diagnosis , Premenstrual Syndrome/epidemiology , Premenstrual Syndrome/etiology , Premenstrual Syndrome/therapy , Vitex , /administration & dosage , Life Style , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL